128940 — Hanmi Pharm Co Income Statement
0.000.00%
- KR₩6tn
- KR₩6tn
- KR₩2tn
Annual income statement for Hanmi Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,203,186 | 1,331,547 | 1,490,887 | 1,495,502 | 1,547,531 |
| Cost of Revenue | |||||
| Gross Profit | 632,752 | 718,553 | 829,249 | 817,037 | 884,407 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,078,723 | 1,178,204 | 1,276,187 | 1,281,798 | 1,292,739 |
| Operating Profit | 124,462 | 153,343 | 214,701 | 213,703 | 254,792 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 103,697 | 121,013 | 193,967 | 171,254 | 213,478 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 81,478 | 101,558 | 165,366 | 140,431 | 187,136 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 67,025 | 82,792 | 146,231 | 121,315 | 169,554 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 67,025 | 82,792 | 146,231 | 121,315 | 169,554 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 5,394 | 6,801 | 11,806 | 9,726 | 13,563 |
| Dividends per Share |